Cargando…

Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function

To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario. Cardiac, renal, electrolytes and hepatic parameters as well as the clinical outcomes were assessed. Levosim...

Descripción completa

Detalles Bibliográficos
Autores principales:	John, Basil, Babu, Mariya, shaji, Sandramol, Abraham, Suja, Abdullakutty, Jabir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322823/ https://www.ncbi.nlm.nih.gov/pubmed/34154760 http://dx.doi.org/10.1016/j.ihj.2021.02.010

Ejemplares similares

Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
por: Juguet, William, et al.
Publicado: (2020)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study
por: Çavuşoğlu, Yüksel, et al.
Publicado: (2016)

Levosimendan versus dobutamine in septic shock
por: Alhashemi, JA, et al.
Publicado: (2009)

Levosimendan versus dobutamine in cardiac surgery
por: Delgado-Amaya, MD, et al.
Publicado: (2015)

Levosimendan versus dobutamine in Tako-tsubo cardiomyopathy
por: Righetti, FR, et al.
Publicado: (2013)

The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure
por: Michalopoulou, H, et al.
Publicado: (2007)

Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction – A multicenter study
por: Bahuleyan, C.G., et al.
Publicado: (2018)

Newer treatments for decompensated heart failure: focus on levosimendan
por: Follath, Ferenc
Publicado: (2009)

Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department
por: Joseph, Jeeva, et al.
Publicado: (2020)

The effects of levosimendan and dobutamine in experimental bupivacaine-induced cardiotoxicity
por: Kandemir, Ulku, et al.
Publicado: (2013)

Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism
por: Lyhne, Mads D., et al.
Publicado: (2021)

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021)

Combined effects of ivabradine with dobutamine or levosimendan in isolated perfused hearts
por: Konrad, D, et al.
Publicado: (2013)

Effect of β-blockade on the haemodynamic responses of levosimendan and dobutamine in the treatment of low-output heart failure
por: Follath, F, et al.
Publicado: (2002)

Levosimendan in patients with low ejection fraction undergoing cardiac surgery
por: Kucewicz-Czech, Ewa M., et al.
Publicado: (2018)

Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double‐Blind Controlled Trial
por: Lannemyr, Lukas, et al.
Publicado: (2018)

Influence of temperature on the cardiac action of dobutamine and levosimendan in isolated perfused hearts
por: Aldenhoff, U, et al.
Publicado: (2013)

The Utility of Low-Dose-Dobutamine Stress Echocardiography in Patients with Heart Failure with Reduced Ejection Fraction: An Update
por: Tsigkriki, Lamprini, et al.
Publicado: (2023)

Pro‐Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction
por: Abernethy, Abraham, et al.
Publicado: (2018)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Clinical and Imaging Parameters Associated With Impaired Kidney Function in Patients With Acute Decompensated Heart Failure With Reduced Ejection Fraction
por: Cho, In-Jeong, et al.
Publicado: (2023)

Levosimendan use in the emergency management of decompensated peripartum cardiomyopathy
por: Uriarte-Rodríguez, Alina, et al.
Publicado: (2010)

ACUTE MYOCARDITIS AND ACUTE DECOMPENSATED HEART FAILURE WITH REDUCED EJECTION FRACTION IN COVID-19
por: Choudhary, Khushal, et al.
Publicado: (2021)

Dobutamine-sparing strategy in managing patients with impaired ejection fraction undergoing coronary artery bypass grafting: less is more?
por: Lin, Xiao-Ming, et al.
Publicado: (2021)

Levosimendan improves hemodynamic effects in patients with acutely decompensated heart failure: the Argentinean multicenter registry
por: Perrone, SV, et al.
Publicado: (2003)

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure
por: Suominen, Pertti K
Publicado: (2011)

The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure
por: Korkmaz, Hasan, et al.
Publicado: (2019)

The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction
por: Bahouth, Fadel, et al.
Publicado: (2021)

Prognostic Importance of Pulmonary Arterial Capacitance in Acute Decompensated Heart Failure With Preserved Ejection Fraction
por: Nakagawa, Akito, et al.
Publicado: (2021)

Clinical Determinants of Quality of Life in Patients With Acute Decompensated Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT-Heart Failure With Preserved Ejection Fraction Registry
por: Seo, Masahiro, et al.
Publicado: (2022)

Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial
por: Meng, Jian-biao, et al.
Publicado: (2016)

Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis
por: Liu, Dong-Hua, et al.
Publicado: (2021)

Levosimendan preconditioning in patients undergoing elective cardiac surgery with poor ejection fraction. preliminary results.
por: Ávalos, R, et al.
Publicado: (2015)

Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies
por: Pereira-Barretto, AC, et al.
Publicado: (2003)

Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India
por: Kaul, U., et al.
Publicado: (2020)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
por: Mebazaa, A, et al.
Publicado: (2004)

Acute decompensated heart failure (ADHF) during COVID-19 pandemic-insights from South India
por: Jayagopal, P.B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l11tkna650hopbcj6jt09op2ie